United States Biotechnology & Medical Research

Summit Therapeutics Inc (SMMT)

Track

Over the past 90 days, Summit Therapeutics Inc. insiders have executed six buy transactions totaling approximately $103.6 million. These purchases were made exclusively by three executives, including the Co-CEOs. This activity occurs amid a 35.7% decline in stock price over the same period and follows the company's most recent earnings report.
Ticker: SMMT Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Summit Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 12 Jun 2026
Value US$3,169,518.25 | Price 489.16 | Shares 89,351 (-24.0%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-12 2026-06-12 B Purchase
4.1
Zanganeh Mahkam

Co-Chief Executive Officer

Executive Director Large shareholder
89,351 -24.0%
489.16
US$3,169,518 		89,351 -24.0% 489.16 US$3,169,518
2026-06-12 2026-06-12 B Purchase
4.3
DUGGAN ROBERT W

Co-Chief Executive Officer

Executive Director Large shareholder
25,195 -20.7%
469.68
US$3,067,907 		25,195 -20.7% 469.68 US$3,067,907
2026-06-04 2026-06-04 B Purchase
4.3
DUGGAN ROBERT W

Co-Chief Executive Officer

Executive Director Large shareholder
46,835 +7.9%
215.87
US$2,737,097 		46,835 +7.9% 215.87 US$2,737,097
2026-06-04 2026-06-04 B Purchase
4.1
Zanganeh Mahkam

Co-Chief Executive Officer

Executive Director Large shareholder
100,000 +0.4%
14.60
US$1,460,000 		100,000 +0.4% 14.60 US$1,460,000
2026-06-04 2026-06-04 B Purchase
3.5
Soni Manmeet Singh

COO and CFO

Executive Director
25,000 +0.8%
14.43
US$360,750 		25,000 +0.8% 14.43 US$360,750
2026-06-04 2026-06-04 B Purchase
3.5
Soni Manmeet Singh

COO and CFO

Executive Director
25,000 +0.8%
14.46
US$361,500 		25,000 +0.8% 14.46 US$361,500
2025-10-23 2025-10-21 B Purchase
0.7
Xia Yu
Non-Executive Director
533,617 +1.7%
18.74
US$9,999,983 		533,617 +1.7% 18.74 US$9,999,983
2025-10-23 2025-10-21 B Purchase
4.3
DUGGAN ROBERT W

Co-Chief Executive Officer

Executive Director Large shareholder
26,680 +53.4%
18.74
US$499,983 		26,680 +53.4% 18.74 US$499,983
2025-10-23 2025-10-21 B Purchase
4.1
Zanganeh Mahkam

Co-Chief Executive Officer

Executive Director Large shareholder
26,680 +53.4%
18.74
US$499,983 		26,680 +53.4% 18.74 US$499,983
2025-09-11 2025-09-11 B Purchase
4.3
DUGGAN ROBERT W

Co-Chief Executive Officer

Executive Director Large shareholder
5,000 +0.0%
18.07
US$90,350 		5,000 +0.0% 18.07 US$90,350
2025-09-11 2025-09-11 B Purchase
4.1
Zanganeh Mahkam

Co-Chief Executive Officer

Executive Director Large shareholder
5,000 +0.0%
18.07
US$90,350 		5,000 +0.0% 18.07 US$90,350
2025-09-11 2025-09-10 B Purchase
4.3
DUGGAN ROBERT W

Co-Chief Executive Officer

Executive Director Large shareholder
333,394 +0.1%
17.68
US$5,894,406 		333,394 +0.1% 17.68 US$5,894,406
2025-09-11 2025-09-10 B Purchase
4.1
Zanganeh Mahkam

Co-Chief Executive Officer

Executive Director Large shareholder
333,394 +0.1%
17.68
US$5,894,406 		333,394 +0.1% 17.68 US$5,894,406
2024-03-27 2024-03-27 B Purchase
4.1
Zanganeh Mahkam

Chief Executive Officer

Executive Director
20,000 +66.7%
3.71
US$74,200 		20,000 +66.7% 3.71 US$74,200
2024-03-27 2024-03-27 B Purchase
4.1
Zanganeh Mahkam

Chief Executive Officer

Executive Director
34,321 +0.1%
3.72
US$127,674 		34,321 +0.1% 3.72 US$127,674
2024-03-27 2024-03-27 B Purchase
4.1
Zanganeh Mahkam

Chief Executive Officer

Executive Director
26,000 +5.3%
3.72
US$96,720 		26,000 +5.3% 3.72 US$96,720
2024-03-27 2024-03-26 B Purchase
3.9
Dhingra Ankur

Chief Financial Officer

Officer
100,000 +39.2%
3.75
US$375,000 		100,000 +39.2% 3.75 US$375,000
2024-03-27 2024-03-26 B Purchase
4.1
Zanganeh Mahkam

Chief Executive Officer

Executive Director
30,000 +inf%
3.75
US$112,500 		30,000 +inf% 3.75 US$112,500
2023-12-13 2023-12-13 B Purchase
3.9
Dhingra Ankur

Chief Financial Officer

Officer
19,700 +8.4%
2.17
US$42,749 		19,700 +8.4% 2.17 US$42,749
2023-12-13 2023-12-13 B Purchase
3.9
Dhingra Ankur

Chief Financial Officer

Officer
700 +0.3%
2.15
US$1,505 		700 +0.3% 2.15 US$1,505
2023-12-13 2023-12-12 B Purchase
4.1
Zanganeh Mahkam

Chief Executive Officer

Executive Director
5,000 +1.0%
2.07
US$10,350 		5,000 +1.0% 2.07 US$10,350
2023-10-16 2023-10-13 B Purchase
3.5
Soni Manmeet Singh

Chief Operating Officer

Executive Director
2,976,190 +inf%
1.68
US$4,999,999 		2,976,190 +inf% 1.68 US$4,999,999
2023-03-08 2023-03-08 B Purchase
4.1
Zanganeh Mahkam

Co-Chief Executive Officer

Executive Director
6,748,629 +215.2%
1.05
US$7,086,060 		6,748,629 +215.2% 1.05 US$7,086,060
2023-03-08 2023-03-08 B Purchase
4.1
Zanganeh Mahkam

Co-Chief Executive Officer

Executive Director
804,672 +215.2%
1.05
US$844,906 		804,672 +215.2% 1.05 US$844,906
2023-03-08 2023-03-08 B Purchase
4.1
Zanganeh Mahkam

Co-Chief Executive Officer

Executive Director
15,973,743 +215.2%
1.05
US$16,772,430 		15,973,743 +215.2% 1.05 US$16,772,430
2023-03-08 2023-03-07 B Purchase
3.9
Dhingra Ankur

Chief Financial Officer

Officer
196,362 +514.1%
1.05
US$206,180 		196,362 +514.1% 1.05 US$206,180
2023-03-08 2023-03-06 B Purchase
4.3
DUGGAN ROBERT W

Chief Executive Officer

Executive Director
376,489,880 +214.1%
1.05
US$395,314,374 		376,489,880 +214.1% 1.05 US$395,314,374
2022-08-18 2022-08-16 B Purchase
4.1
Zanganeh Maky

Co-CEO & President

Executive Director
1,030,925 +49.0%
0.97
US$999,997 		1,030,925 +49.0% 0.97 US$999,997
2022-08-18 2022-08-16 B Purchase
4.1
Zanganeh Maky

Co-CEO & President

Executive Director
4,593,777 +186.2%
0.97
US$4,455,964 		4,593,777 +186.2% 0.97 US$4,455,964
2022-08-18 2022-08-16 B Purchase
4.1
Zanganeh Maky

Co-CEO & President

Executive Director
184,430 +105.1%
0.97
US$178,897 		184,430 +105.1% 0.97 US$178,897
2022-08-18 2022-08-16 B Purchase
4.3
DUGGAN ROBERT W

Chief Executive Officer

Executive Director
94,849,203 +140.1%
0.97
US$92,003,727 		94,849,203 +140.1% 0.97 US$92,003,727
2022-08-17 2022-08-16 B Purchase
3.9
Dhingra Ankur

Chief Financial Officer

Officer
24,658 +182.1%
0.97
US$23,918 		24,658 +182.1% 0.97 US$23,918
2022-08-17 2022-08-16 B Purchase
3.9
Dhingra Ankur

Chief Financial Officer

Officer
11,557 +43.6%
0.97
US$11,210 		11,557 +43.6% 0.97 US$11,210
2021-05-14 2021-05-12 B Purchase
4.1
Zanganeh Maky

Chief Operating Officer

Executive Director
389,077 +17.3%
5.24
US$2,038,763 		389,077 +17.3% 5.24 US$2,038,763
2021-05-14 2021-05-12 B Purchase
4.3
DUGGAN ROBERT W

Chief Executive Officer

Executive Director Large shareholder
11,365,921 +20.2%
5.24
US$59,557,426 		11,365,921 +20.2% 5.24 US$59,557,426
2020-12-01 2020-11-30 S Sale
0.9
Powell David Jonathan

Chief Scientific Officer

Officer
13,713 -100.0%
4.44
US$60,886 		13,713 -100.0% 4.44 US$60,886
2020-12-01 2020-11-27 S Sale
0.9
Powell David Jonathan

Chief Scientific Officer

Officer
29,569 -100.0%
4.39
US$129,808 		29,569 -100.0% 4.39 US$129,808
2020-11-25 2020-11-25 S Sale
0.9
Powell David Jonathan

Chief Scientific Officer

Officer
12,070 -100.0%
4.32
US$52,142 		12,070 -100.0% 4.32 US$52,142
2020-11-25 2020-11-24 S Sale
0.9
Powell David Jonathan

Chief Scientific Officer

Officer
11,374 -100.0%
4.21
US$47,885 		11,374 -100.0% 4.21 US$47,885
2020-11-25 2020-11-23 S Sale
0.9
Powell David Jonathan

Chief Scientific Officer

Officer
6,987 -100.0%
4.40
US$30,743 		6,987 -100.0% 4.40 US$30,743
2020-11-10 2020-11-06 B Purchase
4.3
DUGGAN ROBERT W

Chief Executive Officer

Executive Director Large shareholder
14,071,856 +33.3%
3.34
US$46,999,999 		14,071,856 +33.3% 3.34 US$46,999,999
Explore more

More insider trading research around Summit Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America